AI-assisted lung cancer screening for non-smokers with a family history
Tests an AI-assisted low-dose chest CT screening program in adults aged 50 to 75.
Plain-language title generated from the registry record
Registry title: Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
Key facts
- Where
- Hong Kong, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 75 years old?
Source: NCT06295497, who can take part
Where in Hong Kong
- Department of Clinical Oncology, Prince of Wales HospitalHong Kong, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT06295497
- Record updated
- 18 March 2026
- Original description
Lung cancer screening is currently not recommended in non-smokers due to paucity of evidence. Emerging evidence suggests that first-degree family history is a strong risk factor for lung cancer in Asian non-smokers. In Asia, lack of resource is a major challenge in successful implementation of lung cancer screening. Artificial intelligence (AI) is a promising tool to overcome this resource. In this study, we aim to study the clinical utility and demonstrate the feasibility of using an AI assisted programme for lung cancer screening in Asian non-smokers with a positive family history. This is a single-arm non-randomized lung cancer screening study. 3000 non-smokers, age 50 to 75 year old, with a first-degree family history of lung cancer, will be enrolled. Participants will undergo low does computed tomography (LDCT) of thorax and blood taking at enrolment. LDCT films will be interpreted by AI softwares for presence of lung nodules. Participants with lung nodules will be further investigated and followed up according to the risk of malignancy. The primary endpoint is the prevalence of early-staged lung cancer detected by first-round LDCT thorax in this population.Read full original descriptionShow less
A Prospective Study on Artificial Intelligence Guided Lung Cancer Screening for High-risk Never Smokers in Hong Kong
Lung cancer screening is currently not recommended in non-smokers due to paucity of evidence. Emerging evidence suggests that first-degree family history is a strong risk factor for lung cancer in Asian non-smokers. In Asia, lack of resource is a major challenge in successful implementation of lung cancer screening. Artificial intelligence (AI) is a promising tool to overcome this resource. In this study, we aim to study the clinical utility and demonstrate the feasibility of using an AI assisted programme for lung cancer screening in Asian non-smokers with a positive family history. This is a single-arm non-randomized lung cancer screening study. 3000 non-smokers, age 50 to 75 year old, with a first-degree family history of lung cancer, will be enrolled. Participants will undergo low does computed tomography (LDCT) of thorax and blood taking at enrolment. LDCT films will be interpreted by AI softwares for presence of lung nodules. Participants with lung nodules will be further investigated and followed up according to the risk of malignancy. The primary endpoint is the prevalence of early-staged lung cancer detected by first-round LDCT thorax in this population.
Inclusion: Patients are eligible to be included in the study only if all of the following criteria apply:; Age 50-75 years old; Non-smoker (defined as less than 100 cigarettes in lifetime); Having a first-degree family history of lung cancer; Physically fit for curative treatment if early-staged lung cancer is found; Able to provide written informed consent; Consent to follow up visits and follow up CT scan if indicated; Consent to blood taking for translational research.
Exclusion: History of malignancy; Clinical symptoms suspicious for lung cancer e.g. haemoptysis, chest pain, weight loss; Medical comorbidities that preclude curative treatment (surgery) for lung cancer, such as severe heart disease, acute or chronic respiratory failure, home oxygen therapy, bleeding disorder; History of tuberculosis or interstitial lung disease; CT thorax or chest performed within 2 years (including LDCT, PET-CT, MRI thorax or suspicious of lung cancer); Patients who meet any of the following exclusion criteria at screening are not eligible to be enrolled in this study:; Smoking history (defined as more than 100 cigarettes in lifetime); Pregnant ladies or ladies planning for conception; Pneumonia requiring antibiotic treatment within the last 12 weeks; Unable or unwilling to provide written informed consent.